Now I understand why biotechs are so risky. Not only is there the risk of failing a clinical trial, but there is also the risk of the share price dropping even if you have a successful clinical trial.
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-502
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $1.302M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 713153 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 215665 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |